Arovella Therapeutics Ltd (ASX: ALA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Arovella Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$78.58 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.21 billion
Earnings per share
-0.007
Dividend per share
N/A
Year To Date Return
-30.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Arovella Therapeutics Ltd (ASX: ALA)
Latest News
ASX Share Market News
Suda Pharmaceuticals share price soars 200% on TGA approval
ALA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Arovella Therapeutics Ltd
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. Its activities include pharmaceutical development of drug delivery technology and medical devices and consumables distribution. The company operates through following business segment: Suda; and Malaria Research Company. The Suda segment includes research and development to create new human pharmaceutical products by combining proven drugs with innovated, patented, delivery technologies. The Malaria Research Company segment segment is the pharmaceutical development segment for the treatment of malaria. Arovella Therapeutics was founded on December 21, 1999 and is headquartered in Osborne Park, Australia.
ALA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 21 Aug 2026 | $0.07 | $0.00 | 0.00% | 787,593 | $0.07 | $0.07 | $0.06 |
| 20 Aug 2026 | $0.06 | $0.00 | 0.00% | 118,976 | $0.06 | $0.07 | $0.06 |
| 19 Aug 2026 | $0.06 | $0.00 | 0.00% | 449,817 | $0.06 | $0.07 | $0.06 |
| 18 Aug 2026 | $0.06 | $0.00 | 0.00% | 256,915 | $0.07 | $0.07 | $0.06 |
| 17 Aug 2026 | $0.07 | $0.00 | 0.00% | 1,397,372 | $0.06 | $0.07 | $0.06 |
| 14 Aug 2026 | $0.06 | $0.00 | 0.00% | 840,410 | $0.06 | $0.06 | $0.06 |
| 13 Aug 2026 | $0.06 | $0.00 | 0.00% | 406,023 | $0.06 | $0.06 | $0.06 |
| 12 Aug 2026 | $0.06 | $0.00 | 0.00% | 1,276,812 | $0.06 | $0.06 | $0.06 |
| 11 Aug 2026 | $0.06 | $0.00 | 0.00% | 929,636 | $0.06 | $0.06 | $0.06 |
| 10 Aug 2026 | $0.06 | $0.00 | 0.00% | 668,363 | $0.06 | $0.06 | $0.06 |
| 07 Aug 2026 | $0.06 | $0.00 | 0.00% | 460,485 | $0.06 | $0.06 | $0.06 |
| 06 Aug 2026 | $0.06 | $0.00 | 0.00% | 899,067 | $0.06 | $0.06 | $0.06 |
| 05 Aug 2026 | $0.06 | $0.00 | 0.00% | 96,083 | $0.06 | $0.06 | $0.06 |
| 04 Aug 2026 | $0.06 | $0.00 | 0.00% | 88,591 | $0.06 | $0.06 | $0.06 |
| 03 Aug 2026 | $0.06 | $0.00 | 0.00% | 167,200 | $0.06 | $0.06 | $0.06 |
| 31 Jul 2026 | $0.06 | $0.00 | 0.00% | 616,426 | $0.06 | $0.06 | $0.06 |
| 30 Jul 2026 | $0.06 | $0.00 | 0.00% | 1,224,504 | $0.06 | $0.06 | $0.06 |
| 29 Jul 2026 | $0.06 | $0.00 | 0.00% | 1,437,635 | $0.06 | $0.06 | $0.06 |
| 28 Jul 2026 | $0.06 | $0.00 | 0.00% | 265,398 | $0.06 | $0.06 | $0.06 |
| 27 Jul 2026 | $0.06 | $0.00 | 0.00% | 855,690 | $0.06 | $0.07 | $0.06 |
| 24 Jul 2026 | $0.06 | $0.00 | 0.00% | 208,094 | $0.06 | $0.06 | $0.06 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 09 Jun 2026 | David Williams | Buy | 200,000 | $13,400 |
On-market trade.
|
| 24 Nov 2025 | Elizabeth Stoner | Exercise | 1,157,647 | $96,084 |
Exercise of options.
|
| 24 Nov 2025 | Elizabeth Stoner | Expiry | 1,242,353 | $103,115 |
Options expired.
|
| 24 Nov 2025 | Elizabeth Stoner | Buy | 1,157,647 | $96,084 |
Exercise of options.
|
| 12 Nov 2025 | Debora Barton | Exercise | 1,013,333 | $52,693 |
Exercise of options.
|
| 12 Nov 2025 | Debora Barton | Expiry | 1,386,667 | $133,120 |
Options expired.
|
| 12 Nov 2025 | Debora Barton | Buy | 1,013,333 | $97,279 |
Exercise of options.
|
| 10 Nov 2025 | Gary Phillips | Issued | 1,160,000 | $103,240 |
Issue of options.
|
| 10 Nov 2025 | Michael Baker | Issued | 1,831,266 | $162,982 |
Issue of options.
|
| 13 Oct 2025 | Michael Baker | Exercise | 1,617,021 | $121,276 |
Exercise of options.
|
| 13 Oct 2025 | Michael Baker | Issued | 1,617,021 | $121,276 |
Exercise of options.
|
| 13 Oct 2025 | Michael Baker | Expiry | 6,382,979 | $600,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David John Williams | Non-Executive DirectorNon-Executive Chairman | Apr 2026 |
Mr Williams is a director and corporate advisor with over 4 decades experience in advising ASX listed companies with expertise in business development, M&A and capital markets. Mr Williams is currently the director of RMA Global Limited (ASX:RMY) and Kidder Williams Limited.
|
| Mr Mark P Diamond | Non-Executive Director | Apr 2026 |
Mr Diamond is a executive, who previously served as CEO of Antisense Therapeutics Limited (now Percheron Therapeutics ASX:PER). Mr Diamond has a record in funding, licencing deals, and partnerships. He is currently Biotech Advisor to Spark Plus and Locust Walk, and his global C-Suite executive leadership experience spans healthcare strategy, compliance and risk management, financial management, and board governance. Mr Diamond is currently non-executive chair of Dimerix Ltd (ASX:DXB).
|
| Dr Michael S Perry | Non-Executive Director | Apr 2026 |
--
|
| Dr Michael Joseph Thurn | Non-Executive Director | Apr 2026 |
Mr Thurn is a biotechnology executive and company director with more than 25 years experience across drug discovery, preclinical and clinical development, regulation, commercialisation, capital raising and corporate leadership. He has held executive roles in both private and ASX-listed life sciences companies, including as Managing Director and Chief Executive Officer of Neurizon Therapeutics Limited (ASX: NUZ) (formerly PharmAust Limited), co-founder and Executive Director of MARP Therapeutics, Chief Operating Officer and Executive Director of Botanix Pharmaceuticals, and Chief Executive Officer of Mimetica and Spinifex Pharmaceuticals. He has also served in regulatory review at the Therapeutic Goods Administration. Mr Thurn is currently a director of Neurizon Therapeutics Limited (ASX: NUZ), until July 2026.
|
| Dr Nicole Louise van der Weerden | Acting Chief Executive Officer | May 2026 |
-
|
| Mr Lachie Mallia | Chief Financial OfficerCompany Secretary | Jan 2026 |
-
|
| Nicole Louise van der Weerden | Acting Chief Executive Officer |
-
|
|
| Lachie Mallia | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr. Nicole van der Weerden | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Merchant Funds Management | 68,677,966 | 5.78% |
| Richard John Mann | 68,487,674 | 5.76% |
| Netwealth Investments Limited Wrap Services A/C | 32,788,389 | 2.76% |
| Netwealth Investments Limited Super Services A/C | 30,519,572 | 2.57% |
| UBS Nominees Pty Ltd | 29,070,196 | 2.45% |
| MB Investment Capital Pty Ltd | 27,749,415 | 2.33% |
| Blackburne Capital Pty Ltd Blackburne Capital A/C | 23,008,988 | 1.94% |
| Ajava Holdings Pty Ltd | 23,000,000 | 1.94% |
| Mr James Evan Hughes Morris | 18,857,522 | 1.59% |
| Legacy Asset Holdings Pty Ltd | 18,693,494 | 1.57% |
| DP Investment Capital Pty Ltd | 18,000,000 | 1.51% |
| Dylide Pty Ltd | 16,227,481 | 1.37% |
| M & M Stock One Pty Ltd The M & M Stock One A/C | 15,087,106 | 1.27% |
| Mr Neil Donald Delroy Ndd Investment A/C | 14,167,222 | 1.19% |
| J P Morgan Nominees Australia Pty Limited | 13,234,438 | 1.11% |
| BNP Paribas Noms Pty Ltd | 12,029,212 | 1.01% |
| Moovnup Pty Ltd Moovnup A/C | 11,593,075 | 0.98% |
| Widerange Corporation Pty Ltd | 10,390,789 | 0.87% |
| Citicorp Nominees Pty Limited | 9,677,162 | 0.81% |
| Mr Brendan John Martin & Mrs Sharon Ann Martin Jaknic Super A/C | 9,564,970 | 0.80% |
